Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis

Bon San Koo, Kyu Yong Park, Hyun Jung Lee, Hyun Jung Kim, Hyeong Sik Ahn, Shin-Young Yim and Jae-Bum Jun

Abstract

Background: This study aimed to analyze the literature systematically to determine the clinical characteristics and prognosis of patients with connective tissue disease (CTD) with combined pulmonary fibrosis and emphysema (CPFE) compared to those of patients with CTD-interstitial lung disease (CTD-ILD) without emphysema.

Methods: We searched MEDLINE, EMBASE, Cochrane Library, and KoreaMed for relevant articles published before July 2019. Studies meeting all the following criteria were included: (1) original research studies evaluating the effect of CPFE on CTD, (2) studies that compared patients with CTD-CPFE to those with CTD-ILD without emphysema, and (3) studies providing data on physical capacity, pulmonary function, or death in patients with CTD. Clinical characteristics of patients with CTD-CPFE were compared with those of patients with CTD-ILD without emphysema, and the influence of CPFE on physical capacity, pulmonary function, and death was analyzed.

Results: Six studies between 2013 and 2019 were included. Two hundred ninety-nine (29.5%) and 715 (70.5%) patients had CTD-CPFE and CTD-ILD without emphysema, respectively. Regarding the type of CTD, 711 (68.3%) patients had systemic sclerosis, 263 (25.3%) rheumatoid arthritis, and 67 (6.4%) other CTDs. Patients with CTD-CPFE had a higher frequency of pulmonary hypertension and pulmonary fibrosis > 20% of the total lung volume, higher ratio of the forced vital capacity to the diffusion capacity of the lung for carbon monoxide (DLCO), lower arterial oxygen pressure at rest, and lower DLCO compared to those with CTD-ILD without emphysema. In addition, more deaths occurred among those with CTD-CPFE (odds ratio, 2.95; 95% confidence interval, 1.75–4.96).

Conclusion: CTD-CPFE is associated with worse physical and pulmonary function and more deaths compared to those in CTD-ILD without emphysema. These findings indicate the need for increased awareness and close monitoring of patients with CTD-CPFE.

Keywords: Pulmonary fibrosis, Emphysema, Interstitial lung diseases, Connective tissue diseases, Systematic review, Meta-analysis

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Interstitial lung disease (ILD) is characterized by fibrotic features generally in the lung bases of patients with connective tissue diseases (CTDs), such as rheumatoid arthritis (RA) and systemic sclerosis (SSc), observed on chest computed tomography (CT), high-resolution computed tomography (HRCT), and chest X-ray. Particularly, clinically significant ILD occurs in up to 40% of patients with SSc [1] and significantly increases the mortality rate [2]. As such, ILD has been recognized as an important clinical manifestation, specifically in the prognosis of patients with CTD. Recently, several studies reported that combined pulmonary fibrosis and emphysema (CPFE), as well as ILD, is a pulmonary manifestation within the spectrum of lung disease associated with CTD [3–8].

CPFE, which is characterized by the presence of both emphysema and interstitial pulmonary fibrosis, is a new disease; it exhibits distinct clinical, functional, radiological, and pathological characteristics [9]. The radiologic findings typically include upper-lobe centrilobular and/or paraseptal emphysema and a lower-lobe interstitial fibrotic pattern. In addition, most patients with CPFE have a mixed pattern of pulmonary function and marked reduction in the diffusion capacity of the lung for carbon monoxide (DLCO) [10]. Thus, complications such as acute lung injury, lung cancer, and pulmonary arterial hypertension may occur. The prevalence of pulmonary hypertension has been reported as 47–90%, which is much higher than the prevalence of chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF). Moreover, patients with CPFE-associated pulmonary hypertension have a poorer survival rate than those with COPD-associated or IPF-associated pulmonary hypertension [11–13]. Thus, CPFE in patients with CTD should also be recognized as an important pulmonary manifestation. However, the exact prevalence and clinical features are not well known.

Hence, in this systematic investigation, we aimed to determine the prevalence and characteristics of CPFE compared to those of ILD without emphysema in patients with CTD. In addition, by subgroup analysis, CPFE was compared with ILD with emphysema in patients with systemic sclerosis (SSc), which is one of the diseases of CTD.

Methods
We searched MEDLINE, EMBASE, Cochrane Library, and KoreaMed for relevant articles published before July 2019. Studies were included in this systematic review if they met all of the following inclusion criteria: (1) original research studies evaluating the effect of CPFE on CTD, (2) studies that compared patients with CTD-CPFE to those with CTD-ILD without emphysema, and (3) studies providing data on physical capacity, pulmonary function, or death in patients with CTD. Studies with fewer than five cases, animal studies, review articles, and studies on patients aged ≤5 years were excluded.

Two investigators (KYP and SYY) independently performed data extraction using a predefined form. Any disagreement unresolved by discussion was reviewed by a third author (JBJ). The following variables were extracted from the studies: (1) demographic characteristics, including the first author’s name, year of publication, country where the study was performed, number of subjects, sex, and age; (2) type and diagnostic criteria for CTD; (3) the diagnostic method of CPFE and ILD without emphysema; (4) smoking history; (5) physical characteristics (such as the presence of anti-centromere antibodies, digital ulcers, and pulmonary hypertension), composite physiologic index, extent of pulmonary fibrosis, and partial pressure of arterial oxygen at rest; (6) pulmonary function test results and DLCO; (7) 6-min walk test results; and (8) the number of deaths.

The effect of CPFE on patients with CTD was analyzed in terms of physical capacity, pulmonary function, and death, and patients with CPFE were compared to those with ILD without emphysema. A subgroup analysis of the effects of CPFE was conducted for SSc because lung involvement in SSc is a major factor in the prognosis.

Assessment of methodological quality
Two investigators (KYP and SYY) independently assessed the methodological quality of each study using the Newcastle-Ottawa Scale for assessing the risk of bias for non-randomized studies [14]. The Newcastle-Ottawa Scale is a tool used to assess the quality of non-randomized studies included in systematic reviews and/or meta-analyses. Each study was evaluated according to eight items, which were categorized as follows: selection of the study groups, comparability of the groups, and either the exposure or outcome of interest for case-control or cohort studies. The evaluation method included assigning stars to each study; the study with the highest quality may receive up to 10 stars. This method provides a quick visual assessment of the quality of a study. The score in the Newcastle-Ottawa Scale ranges from 0 to 10, where 10 indicates the highest methodological quality. Any discrepancies were addressed by a joint re-evaluation of the original article by a third author.

Statistical analysis
The meta-analysis was performed using the Review Manager Software (RevMan version 5.3., Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2014). The pooled mean difference (MD; with 95% confidence interval [CI]) in physical capacity and
pulmonary function between patients with CTD-CPFE and those with CTD-ILD without emphysema was calculated using the inverse-variance method. The pooled odds ratio (OR; with 95% CI) was also computed for sex; the number of smokers; the number of patients with anti-centromere antibodies, digital ulcers, and pulmonary hypertension; and the number of deaths for patients with CTD-CPFE and CTD-ILD without emphysema using the Mantel-Haenszel method.

We examined the heterogeneity across studies using the $I^2$ statistic to quantify the percentage of variability that could be attributed to between-study differences. $I^2$ values for all reports were calculated by the random-effects model because of the inherent limitations of non-controlled studies. An $I^2$ value > 50% was considered significantly heterogeneous. Statistical significance was defined as a $p$ value < 0.05.

Results
Identification of studies and assessment of methodological quality
The study selection process is shown in Fig. 1. Among 346 records identified by the database search, six studies published between 2013 and 2019 were included in the analysis. Quality assessment of the six non-randomized studies was performed using the Newcastle-Ottawa Scale (Table 1). The methodological quality was scored as 8 in five non-randomized studies and as 3 in the remaining one study, which was a short report [14].

Study characteristics
The characteristics of the studies are shown in Table 1. A total of 1014 patients with CTD were included (312 [30.8%] men, 702 [69.2%] women). Two hundred ninety-nine (29.5%) patients had CTD-CPFE, and 715 (70.5%) had CTD-ILD without emphysema. Regarding the type of CTD, 745 (73.5%) patients had SSc, 263 (25.9%) RA, and 6 (0.6%) other CTDs. Among the six studies, four were for SSc [3–6], one for RA [7], and one for several CTDs [8]. SSc and RA were diagnosed based on the ACR-EULAR criteria [15–17], and ILD was confirmed by HRCT or CT.

Prevalence of CPFE in patients with CTDs
CPFE prevalence was determined in three studies with a relatively large number of patients with SSc [3–5] (Table 2). In SSc-ILD with or without emphysema, the pooled prevalence of SSc-CPFE was 13.4% (94/703 patients). In a study of 276 patients with SSc, the CPFE prevalence regardless of the presence of ILD was 3.6%; moreover, CPFE was found in 17.4% of smokers and 5.3% of non-smokers [5].

Comparison of clinical features between CTD-CPFE and CTD-ILD without emphysema
The clinical characteristics of CTD-CPFE were compared to those of CTD-ILD without emphysema (Table 3). The CTD-CPFE group had a significantly more prominent smoking history than the CTD-ILD group (six studies with ever-
smokers: OR, 4.84; 95% CI, 3.52–6.65; two studies with current smokers: OR, 2.54; 95% CI, 1.24–5.19; and two studies with the amount of cigarettes smoked: MD, 13.64 pack-years; 95% CI, 7.77–19.48). In terms of physical and laboratory characteristics, the CTD-CPFE group had a higher number of patients with ACA and pulmonary hypertension, and lower arterial oxygen pressure at rest, than the CTD-ILD without emphysema group (two studies: OR, 0.81; 95% CI, 0.31–2.13; two studies: OR, 3.36; 95% CI, 1.85–6.09; and three studies: MD, −0.89 kPa; 95% CI, −1.26 to −0.52). In terms of the pulmonary function test, the CTD-CPFE group had a higher forced vital capacity-to-DLCO ratio, lower DLCO, and lower transfer coefficient of the lung for carbon monoxide than the CTD-ILD without emphysema group (three studies: MD, 0.32; 95% CI, 0.15–0.48; six studies: MD, −12.38%; 95% CI, −15.62 to −9.14; and three studies: MD, −16.53%; 95% CI, −19.93 to −13.13). In terms of the 6-min walk test, the CTD-CPFE group had a shorter walking distance than the CTD-ILD without emphysema group (two studies: MD, −46.44 m; 95% CI, −88.66 to −4.22). Two studies reported 145 deaths (48.5%) among patients with CTD-CPFE and 121 deaths (16.9%) among those with CTD-ILD without emphysema; more deaths were recorded in patients with CTD-CPFE (two studies: OR of death, 2.95; 95% CI, 1.75–4.96).

### Table 1: Characteristics of studies included in the meta-analysis

| Study/year | Country          | Number of subjects with CTD (men/women) | Age of subjects (years; mean ± SD) | CTD Diagnosis method of ILD | NOS score |
|------------|------------------|----------------------------------------|-----------------------------------|-----------------------------|-----------|
|            |                  | Total                                   | CPFE                              | ILD without emphysema       |           |
|            |                  |                                        |                                   |                             | HRCT 8    |
|            |                  | CPFE                                    | ILD without emphysema             |                             |           |
|            |                  |                                        |                                   |                             |           |
| Antoniou et al./2016 [3] | UK  | 333 (74/259)                          | 51.1 ± 15.1                       | SSc                         |           |
| Ariani et al./2019 [4]    | Italy | 239 (52/187)                          | 54.4 ± 12.8                       | SSc                         | CT 3      |
| Champtiaux et al./2018 [5] | France | 108 (40/68)                           | 48.75 ± 17.02                     | SSc                         | HRCT 8    |
| Cottin et al./2011 [6]    | France | 68 (33/35)                             | 57 ± 11                           | SSc                         |           |
| Jacob et al/2018 [7]      | South Korea and UK | 245 (110/135)                        | 63 (median)                       | RA                          | CT 8      |
| Yamakawa et al./2018 [8]  | Japan | 21 (3/18)                              | 60.5 ± 10.5                       | SSc                         | HRCT 8    |
| Total                  |                  | 1014 (312/702)                        | 715 (141/574)                     |                             |           |

### Table 2: Prevalence of CPFE in patients with SSc or SSc-ILD

| Study/year | Number of studied patients (n) | Prevalence (%, n) | SSc-ILD with or without emphysema | SSc-CPFE |
|------------|-------------------------------|------------------|-----------------------------------|----------|
| Antoniou et al./2016 [3] | 333                           | 12.3             | 19.7 (26/132)                     | 7.5 (15/201) |
| Ariani et al./2019 [4]    | 239                           | 18.0             | 14.7 (16/109)                     | 7.1 (25/351) |
| Champtiaux et al./2018 [5] | 131*                          | 7.6              | 10                               | –        |
| Pooled data              | 703                           | 13.4             | 17.4                             | 5.3      |

SSc systemic sclerosis, SSc-ILD the patients with systemic sclerosis and interstitial lung disease, CPFE combined pulmonary fibrosis and emphysema, CTD-CPFE connective tissue disease and combined pulmonary fibrosis and emphysema, CTD-ILD connective tissue disease and interstitial lung disease

*Number of patients with confirmed ILD in patients with SSc
Table 3: Meta-analysis on the effect of combined pulmonary fibrosis and emphysema (CPFE) on connective tissue disease (CTD), compared to interstitial lung disease (ILD) without emphysema

| Characteristics                                      | Number of patients (n = 1014) | Pooled mean difference or odds ratio (95% confidence interval) | Heterogeneity |
|------------------------------------------------------|------------------------------|----------------------------------------------------------------|---------------|
|                                                      | Included study | CTD-CPFE (n = 299) | CTD-ILD without emphysema (n = 715) |                          |                         |                             |
|                                                      | Number of deaths | 2 | 145 | 121 | 2.95 [1.75, 4.96] | 0 | 0.78 |
| Age and gender                                       | 5 | 170 | 599  | 0.23 [−2.44, 2.89] | 0 | 0.50 |
| Age of patients                                      | 6 | 299 | 715  | 4.96 [3.60, 6.82] | 60 | 0.03 |
| Smoking history                                      | 6 | 299 | 715  | 4.84 [3.52, 6.65] | 74 | 0.002 |
| Number of male patients                              | 2 | 77  | 230  | 2.54 [1.24, 5.19] | 0 | 0.92 |
| Number of ever-smokers                               | 2 | 70  | 106  | 13.63 [7.77, 19.48] | 0 | 0.57 |
| Physical and laboratory characteristics               | 2 | 79  | 268  | 0.81 [0.31, 2.13] | 0 | 0.89 |
| Number of patients with ACA                          | 2 | 52  | 77   | 0.64 [0.29, 1.41] | 0 | 0.77 |
| Number of patients with digital ulcer                | 2 | 70  | 98   | 2.46 [−5.33, 10.24] | 70 | 0.07 |
| Composite physiologic index                          | 3 | 186 | 413  | 5.58 [−1.32, 12.47] | 78 | 0.01 |
| ILD extent, % of total lung volume                   | 2 | 75  | 265  | 1.99 [1.18, 3.37] | 22 | 0.26 |
| Number of patients with ILD extent > 20% of total lung volume | 2 | 73  | 361  | 3.36 [1.85, 6.09] | 78 | 0.03 |
| Number of patients with pulmonary hypertension       | 3 | 107 | 382  | −0.89 [−1.26, −0.52] | 0 | 0.92 |
| PaO2 at rest, kPa                                     | 2 | 70  | 104  | 10.55 [−15.91, 37.01] | 89 | 0.003 |
| Pulmonary function test                               | 6 | 299 | 714  | 1.90 [−2.45, 6.26] | 41 | 0.13 |
| TLC, % of predicted                                  | 4 | 240 | 512  | −2.02 [−5.42, 1.37] | 0 | 0.50 |
| RV, % of predicted                                   | 3 | 86  | 109  | −5.45 [−9.10, −1.80] | 57 | 0.10 |
| FEV1, % of predicted                                 | 6 | 113 | 301  | 3.31 [−7.06, 13.69] | 85 | 0.001 |
| FEV1/FVC, % of predicted                             | 2 | 70  | 104  | 10.55 [−15.91, 37.01] | 89 | 0.003 |
| DLCO, % of predicted                                 | 4 | 240 | 512  | −2.02 [−5.42, 1.37] | 0 | 0.50 |
| FVC/DLCO                                             | 3 | 86  | 109  | −5.45 [−9.10, −1.80] | 57 | 0.10 |
| KCO, % of predicted                                  | 6 | 299 | 707  | −12.38 [−15.62, −9.14] | 36 | 0.17 |
| 6-minute walk test (6MWT)                            | 2 | 57  | 297  | 0.32 [0.15, 0.48] | 0 | 0.35 |
| Walking distance in 6MWT, meters                     | 3 | 199 | 214  | −16.53 [−19.93, −13.13] | 0 | 0.63 |
| SPO2 after 6MWT, %                                   | 2 | 70  | 104  | 0.92 [−2.39, 4.23] | 0 | 0.67 |
| Decrease in SpO2 after 6MWT, %                       | 2 | 60  | 74   | −0.62 [−9.83, 8.59] | 93 | 0.0002 |

CTD-CPFE: connective tissue disease and combined pulmonary fibrosis and emphysema, CTD-ILD: connective tissue disease and interstitial lung disease, ACA: anti-centromere antibody, ILD: interstitial lung disease, PaO2: arterial oxygen pressure at rest, TLC: total lung capacity, RV: reserve volume, FEV1: forced expiratory volume in 1 s, FVC: forced vital capacity, DLCO: diffusing capacity of carbon monoxide, KCO: carbon monoxide transfer coefficient, SpO2: peripheral capillary oxygen saturation.
Subgroup analysis of the effects of CPFE in patients with SSc

A meta-analysis on the clinical characteristics of the patients with SSc-CPFE is presented in Table 4; patients with SSc-CPFE were compared to those with SSc-ILD without emphysema. Subgroup analysis of age, sex, smoking history, physical characteristics, pulmonary function test results, and DLCO in patients with SSc-CPFE showed findings similar to those in patients with CTD-CPFE.

Discussion

According to the results of our meta-analysis, patients with CTD-CPFE had different clinical features from those with CTD-ILD without emphysema. Patients with CTD-CPFE had higher rates of pulmonary hypertension and lower physical capacity compared to those with CTD-ILD without emphysema. Importantly, mortality was higher in patients with CTD-CPFE than in those with CTD-ILD without emphysema. In a subgroup analysis of SSc, similar results for the features of CPFE were found in the comparison of SSc-CPFE and SSc-ILD without emphysema. Therefore, the prognosis may be poorer with the presence of CPFE as opposed to pulmonary fibrosis without emphysema in patients with CTD. Notably, a recent CPFE study that included some patients with CTD showed that patients with less fibrosis at baseline (< 5%) had a better prognosis, suggesting that fibrosis has a significant influence on the prognosis [18].

Cottin et al. showed that the smoking history and pulmonary function profile were similar between smoking-related CPFE and CTD-related CPFE. Nevertheless, patients with CTD-related CPFE had a better prognosis compared to those with smoking-related CPFE, and those with CTD-ILD without emphysema had a better prognosis than those with IPF [6]. In the current meta-analysis, we focused on the comparison between CPFE and ILD without emphysema in patients with CTD. Regarding the poorer prognosis for CPFE than for ILD without emphysema in patients with CTD, the presence

Table 4

Meta-analysis on clinical characteristics of the patients with systemic sclerosis (SSc) with combined pulmonary fibrosis and emphysema (CPFE) compared to the patients with SSc with interstitial lung disease (ILD) without emphysema

| Characteristics | Number (n = 701) | Included study | SSc-CPFE (n = 136) | SSc-ILD without emphysema (n = 565) | Pooled mean difference or odds ratio [95% confidence interval] | Heterogeneity | I² (%) | P |
|-----------------|-----------------|----------------|-------------------|-----------------------------------|------------------------------------------------|---------------|--------|----|
| Age and gender  |                 |                |                   |                                   |                                                      |               |        |    |
| Age of patients | 4               | 136            | 565               |                                   | −0.73 [−3.66, 2.19]                         | 0             | 0.83   |    |
| Number of male patients | 4 | 136 | 565 | 3.99 [2.62, 6.06] | 70 | 0.02 |
| Smoking history |                 |                |                   |                                   |                                                      |               |        |    |
| Number of ever-smokers | 4 | 136 | 565 | 3.16 [2.09, 4.78] | 64 | 0.04 |
| Physical characteristics |                 |                |                   |                                   |                                                      |               |        |    |
| Number of patients with ACA | 2 | 79 | 268 | 0.81 [0.31, 2.13] | 0 | 0.89 |
| Number of patients with digital ulcer | 2 | 52 | 77 | 0.64 [0.29, 1.41] | 0 | 0.77 |
| Composite physiologic index | 2 | 70 | 98 | 2.46 [−5.33, 10.24] | 70 | 0.07 |
| ILD extent, % of total lung volume | 2 | 57 | 297 | 7.02 [−4.53, 18.56] | 85 | 0.009 |
| Number of patients with ILD extent > 20% of total lung volume | 2 | 75 | 265 | 1.99 [1.18, 3.37] | 22 | 0.26 |
| Number of patients with pulmonary hypertension | 2 | 73 | 361 | 3.36 [1.85, 6.09] | 78 | 0.03 |
| PaO₂ at rest, kPa | 2 | 73 | 348 | −0.94 [−1.41, −0.47] | 0 | 0.84 |
| Pulmonary function test |                 |                |                   |                                   |                                                      |               |        |    |
| TLC, % of predicted | 2 | 79 | 267 | −1.93 [−6.73, 2.88] | 0 | 0.68 |
| FEV₁, % of predicted | 2 | 77 | 362 | −2.52 [−7.50, 2.45] | 0 | 0.66 |
| FVC, % of predicted | 4 | 136 | 564 | −0.65 [−4.96, 3.66] | 0 | 0.58 |
| FEV₁/FVC, % of predicted | 2 | 52 | 75 | −4.62 [−9.41, 0.17] | 72 | 0.06 |
| DLCO, % of predicted | 4 | 136 | 557 | −14.31 [−17.31, −11.32] | 0 | 0.41 |
| FVC/DLCO | 2 | 57 | 297 | 0.32 [0.15, 0.48] | 0 | 0.35 |

SSc-CPFE systemic sclerosis and combined pulmonary fibrosis and emphysema, SSc-ILD sclerosis and interstitial lung disease, ACA anti-centromere antibody, ILD interstitial lung disease, TLC total lung capacity, FEV₁ forced expiratory volume in 1 s, FVC forced vital capacity, DLCO diffusing capacity of carbon monoxide.
of emphysema might be related to the risk factors in patients with ILD [19].

In SSc, ILD is one of the most common complications and the most common cause of death [20, 21]. The prevalence of CPFE has been reported as 3.6% for SSc and 13.4% for SSc-ILD with or without emphysema [3–5], indicating that some cases are overlooked when evaluating the lung involvement in SSc. Systematic classification and prognosis-related factors for CTD-CPFE as well as idiopathic CPFE should be studied in the future.

Yamakawa et al. conducted a surgical lung biopsy study in 21 patients with SSc-ILD [8]. Pathological pulmonary emphysema was seen in 16 (76.2%) patients, of whom 62.5% were never-smokers. On HRCT, an interstitial abnormality with an area of low attenuation was seen in 31.3% of patients, and this was reported as a novel and radiopathological feature specific to SSc-ILD. However, as the authors pointed out, in the definition of existing CPFE, it should be understood that the pathological pulmonary emphysema shown in the current study and emphysema that appears radiologically predominant in the upper poles on HRCT in other studies have different characteristics. In addition, paraseptal emphysema, which can often be seen in non-smokers, is different from centrilobular emphysema, which is caused by exposure to smoking, on HRCT. These evidences suggest that CPFE in patients with CTD is associated with an immunological mechanism other than the commonly known emphysema.

In our results, the prevalence of CPFE in smokers was 17%, which shows that smoking is a major risk factor for CPFE. However, in non-smokers, the prevalence was 5.3%, suggesting another possible risk factor for CPFE. Studies on RA-ILD conducted in Korea and the UK showed a high CPFE prevalence (27%) in never-smokers [7] and suggested that CPFE is independently associated with a worsened outcome and a definite usual interstitial pneumonia pattern on CT. Therefore, patients with autoimmune diseases, such as SSc, should be carefully monitored for emphysema regardless of smoking using low-dose HRCT and the pulmonary function test, especially for those with ILD. In addition, it is necessary to develop new biomarkers or modalities that can differentiate CPFE and quantify risk.

Moreover, ILD in SSc is more often accompanied by emphysema; thus, the high CPFE prevalence in ILD suggests that ILD itself may be a risk factor for the development of emphysema and that CPFE may be a pulmonary manifestation within the spectrum of CTD-ILD [22]. Interestingly, while smoking is a major risk factor for CPFE, Jacob et al. suggested that the prevalence of emphysema is also high in never-smokers [7]. The mechanism of CPFE should be further clarified in future studies, although several possibilities have been suggested [3, 5, 23].

Our study, which is the first meta-analysis of the effect of CPFE on CTD, has some limitations. First, the small number of studies included in this meta-analysis limits the strength of the evidence regarding the effect of CPFE on the clinical manifestations of CTD. Second, we included various types of CTDs, including extremely rare diseases, in the meta-analysis. While we have conducted a subgroup analysis of SSc, a subgroup analysis of other CTDs with different characteristics, such as RA, is needed. Third, the extent of lesions in ILD and CPFE can vary significantly from patient to patient, when interpreting the results and prognosis.

**Conclusions**

Patients with CTD-CPFE showed greater physical and pulmonary function deterioration, decreased exercise capacity, and increased mortality compared to patients with CTD-ILD without emphysema. Although the prevalence of CTD-CPFE is lower than that of CTD-ILD without emphysema, CPFE should be carefully evaluated using low-dose HRCT and the pulmonary function test.

**Abbreviations**

CTD: Connective tissue disease; CPFE: Combined pulmonary fibrosis and emphysema; ILD: Interstitial lung disease; RA: Rheumatoid arthritis; SSc: Systemic sclerosis; COPD: Chronic obstructive pulmonary disease; MD: Mean difference; CI: Confidence interval; OR: Odds ratio; HRCT: High-resolution computed tomography; DLCO: Diffusing capacity of the lung for carbon monoxide

**Supplementary Information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13075-021-02494-y.

**Authors’ contributions**

SYY and JBJ contributed to the study conception and design. BSK, KYP, HJK, HBL, SYY, and JBJ performed the acquisition of data. BSK, KYP, SYY, and JBJ wrote the manuscript. BSK, KYP, and HJL were involved in the interpretation and analysis of the data. HJK and HSA were involved in the statistical modeling. BSK, HJK, HAS, SYY, and JBJ were involved in the literature search. All authors took part in revising the manuscript critically for important intellectual content, gave their final approval of the version to be published, and agreed to be accountable for all aspects of the work.

**Funding**

This study was supported by grants from the National Research Foundation of Korea (NRF) and the Ministry of Science, ICT, and Future Planning, Republic of Korea (grant number 2019R1H1A2079935).

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.
Declarations

Ethics approval and consent to participate
Ethical approval is not required for this meta-analysis, because this result was from a secondary analysis of data available in previous reports.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, South Korea. 2Department of Physical Medicine and Rehabilitation, Ajou University School of Medicine, Suwon, South Korea. 3Department of Physical Medicine and Rehabilitation, Jeju National University Hospital, Jeju, South Korea. 4Graduate Program of Medicine, Ajou University Graduate School, Suwon, South Korea. 5Department of Preventive Medicine, College of Medicine, Korea University, Seoul, South Korea. 6Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.

Received: 12 October 2020 Accepted: 29 March 2021

Published online: 06 April 2021

References
1. Perelas A, Arrossi AV, Highland KB. Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease. Clin Chest Med. 2019;40(3):501–18. https://doi.org/10.1016/j.ccm.2019.05.001.
2. Elhai M, Meune C, Boubaya M, Avouac J, Hochulla E, Balbir-Gurman A, Riemekasten G, Aröhn P, Joven B, Vettori S, Cozfal F, Ullmann S, Cizjak L, Tikhov M, Müller-Ladner U, Caramaschi P, Distler O, Iannone F, Ananian UP, Hesselstrand R, Bescar R, Gabrielli A, Damijancov S, Salvador M, Ricci C, Mihal C, Szucs G, Walker UA, Hurezelnmann N, Martinovic D, Smith V, Müller CS, Montecucco CM, Opsir D, Ingegnozdi F, Vachhoyapoulos PG, Stenmarkovic B, Rosato E, Heitmann S, Distler JHW, Zenone T, Seidel M, Vaccia A, Langhe E, Novak S, Gutoto M, Mouthoun L, Henes J, Chiennizzi C, Mühlen CAV, Solanki K, Rednic S, Stamp L, Anic B, Santamaria VO, de Santis M, Yavuz S, Sifuentes-Graldo WA, Chatulis E, Elik J, Kost J, Laar LV, Loyo E, Garcia de la Perla Lefebvre P, Eyster K, Cosentino V, Alegre-Sandojo JI, Kowal-Bielecka O, Ray G, Matsuji-Centric M, Alivano V, EULAR group. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897–905. https://doi.org/10.1136/annrheumdis-2017-231148.
3. Antoniou KM, Margaritopoulos GA, Koh NS, Karagiannis K, Desai SR, Nicholson AG, Safakas NM, Coghlan JG, Denton CP, Hansell DM, Wells AU. Combined pulmonary fibrosis and emphysema in systemic sclerosis-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension. Arthritis Rheumatol. 2016;68(4):1004–12. https://doi.org/10.1002/art.39528.
4. Aviani A, Silva M, Bravi EP, Pari S, Saracco M, De Gennaro F, et al. Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis. RMD Open. 2019;5(3):e000820. https://doi.org/10.1136/rmdopen-2018-000820.
5. Champtiaux N, Cottin V, Chassagnon G, Chaigne B, Valeyre D, Nunes H, Hochulla E, Launay D, Cristiani B, Cazals C, Jego P, Bussone G, Berrezé A, Guillemin R, Revel MP, Cottin JF, Mouthoun L, Groupe d’Etudes et de Recherche sur les Maladies « Orphelines » pulmonaires (GERMOnP). Combined pulmonary fibrosis and emphysema in systemic sclerosis: a systemic sclerosis associated with heavy morbidity and mortality. Semin Arthritis Rheum. 2019;49(1):98–104. https://doi.org/10.1016/j.semarthrit.2018.10.011.
6. Cottin V, Nunes H, Mouton L, Gomendes D, Lazor R, Hochulla E, Revel D, Valeyre D, Cordier JF, Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheumatol. 2011;63(1):295–304. https://doi.org/10.1002/art.30077.
7. Jacob J, Song JW, Yoon HY, Coss G, Barnett J, Woo WK, Adame F, Kokosi M, Devajay A, Renzoni E, Maher T, Kim DS, Wells AU. Prevalence and effects of emphysema in nonsmokers with rheumatoid arthritis interstitial lung disease. EBioMedicine. 2018;28:303–10. https://doi.org/10.1016/j.ebiom.2018.10.038.
8. Yamakawa H, Takekuma T, Iwasawa T, Yamanaaka Y, Ikeda S, Sekine A, Kitamura H, Baba T, Ito S, Okudela K, Kuwano K, Ogura T. Emphysematosus change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy? BMC Pulm Med. 2018;18(1):25. https://doi.org/10.1186/s12890-018-0591-y.
9. Cottin V, Nunes H, Billet PY, Delval P, Devauxsouq T, Gille-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct undereognised entity. Eur Respir J. 2005;26(4):856–93. https://doi.org/10.1183/09031936.05020106.
10. Kikkkourouma L, Cottin V, Glerant JC, Bayle Y, MonCM, Cordier JF. Conditions associated with severe carbon monoxide diffusion coefficient reduction. Respir Med. 2011;105(8):1248–56. https://doi.org/10.1016/j.rmed.2011.03.004.
11. Caminiti A, Cassandro R, Harari S. Pulmonary hypertension in chronic interstitial lung diseases. Eur Respir Rev. 2013;22(129):292–301. https://doi.org/10.1183/09059180.00002713.
12. Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35(1):105–11. https://doi.org/10.1183/09031936.00038709.
13. Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25):O19–O6. https://doi.org/10.1016/j.jacc.2013.02.036.
14. Deeks JJ, Dinnes J, D’Amico R, Sowder AJ, Sakarotvich C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7:i–x, 1–173. https://doi.org/10.3310/hta7270.
15. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(6):581–90. https://doi.org/10.1002/art.1780230510.
16. Amet F, Edswardy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):515–24. https://doi.org/10.1002/art.1780310302.
17. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matsuji-Centric M, Naden RP, Medger TA Jr, Carreira PE, Riemekasten G, Cottin V, Distler O, Allareone Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibel JG, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentin P, Goyal C, Venk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kaahrheh B, Merkel PA, Seraevskii S, Silver MS, Simms RW, Varga J, Pope JE. 2015 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2015;67(11):2373–47. https://doi.org/10.1002/art.34809.
18. Nemoto M, Neli Y, Bartholmai B, Yoshida K, Matsui H, Nakashita T, Motojiwa S, Aoshima M, Ryu JH. Automated computed tomography quantification of fibrosis predicts prognosis in combined pulmonary fibrosis and emphysema in a real-world setting: a single-centre, retrospective study. Respir Res. 2020;21(2):275. https://doi.org/10.1186/s12931-020-01154-5.
19. Meija M, Carrillo G, Rojas-Serrano J, Estrada A, Suarez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009;136(1):105–9. https://doi.org/10.1378/chest.08-2306.
20. Steen VD, Medger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(5):940–4. https://doi.org/10.1136/ard.200606608.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.